These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported Terminated||2008-006765-82||Preventive therapy for multidrug-resistant tuberculosis: a multicentre clincal trial.||2014-01-29||due-trials|
|Reported results||2009-016697-32||PRotease-Inhibitors MOnotherapy Strategies as maintenance therapy in persons with fully suppressed HIV replication: results from an open-label randomized comparative trial (PRIMO Trial)||2014-10-27||due-trials|
|Completed, but no date Terminated||2009-016705-42||Pilot study on efficacy of a simplification strategy from DRV/r 600/100 mg BID to DRV/r 800/100mg QD + OBT in HIV-positive patients HAART-experienced with virological response.||bad-data|
|Ongoing||2010-023245-30||Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis||not-yet-due|
|Ongoing||2011-004038-33||Non-inferiority,randomized clinical trial to evaluate the efficacy and the safety of the use of fixed-dose combination efavirenz/tenofovir/emtricitabine (Atripla) administered in alternate days versu...||not-yet-due|
|Completed, but no date Terminated||2011-004693-29||Pegylated interferon alfa-2a USE FOR CONTROLLING virological rebound after suspension of antiretroviral treatment IN PATIENTS WITH CHRONIC HIV INFECTION||bad-data|
|Ongoing||2011-005270-35||HIV-infected pregnant women treated with HAART: registry of pharmacokinetic parameters of new and commonly used antiretrovirals||not-yet-due|
|Ongoing||2014-003874-17||Antiretroviral Pre-exposure prophylaxis for natural conception (PrEP-C) in serodiscordant female partners of HIV-infected men in sustained virologic suppression||not-yet-due|
|Ongoing||2020-001390-76||A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients...||not-yet-due|
|Ongoing||2020-001528-32||Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals||not-yet-due|